Key result
Prostate cancer is linked to increased oxidative and inflammatory markers, with CRP correlating with PSA.
Why the study?
Inflammation and oxidative stress play a key role in the pathogenesis of prostate cancer, but the concentrations of new oxidative stress biomarkers and inflammatory markers in these patients were not well characterized.
Are oxidative stress and inflammatory biomarkers altered in patients with prostate cancer compared to healthy subjects?
Case-Control (n=55)
Are oxidative stress and inflammatory biomarkers altered in patients with prostate cancer compared to healthy subjects?
Inflammatory and oxidative processes are increased, and antioxidant defenses are reduced, in patients with prostate cancer.
Elevated IMA/CRP and lower FRAP in prostate cancer support oxidative-inflammatory hypotheses; leaves open biomarker utility pending prospective validation.
BACKGROUND: Prostate cancer has become a public health problem in many countries and there is evidence which indicates that inflammation and oxidative stress play a key role in the pathogenesis of this disease. Thus, the aim of this study was to evaluate the concentrations of new biomarkers of oxidative stress, ischemia-modified albumin (IMA) and ferric reducing ability of plasma (FRAP), as well as the inflammatory markers in patients with prostate cancer. METHODS: CRP, IMA, FRAP, fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, uric acid, creatinine, albumin, AST, ALT, ADA, total PSA (tPSA), free PSA, and proportion of free PSA (fPSA%) were measured in 25 patients with prostate cancer and in 30 healthy subjects. RESULTS: tPSA, CRP, and IMA were significantly higher in patients with prostate cancer. In contrast, fPSA% and FRAP were significantly lower in these patients. However, no significant differences were observed when IMA values were adjusted for serum albumin. Significant correlations were also observed for tPSA and CRP (r = 0.5104, p < 0.001) and for fPSA% and CRP (r = -0.5059, p < 0.001). CONCLUSIONS: We demonstrated that both inflammatory and oxidative processes are increased during prostate cancer and also that there is a reduction of antioxidant defenses in this pathology.
No takes yet. Share an insight, caveat, or question.
Silveira et al. (2014) conducted a case-control in Prostate cancer (n=55). Prostate cancer vs. Healthy subjects was evaluated on Concentrations of oxidative stress and inflammatory biomarkers (IMA, FRAP, CRP, PSA). Prostate cancer was associated with increased inflammatory and oxidative markers, with significant correlations between CRP and both tPSA (r=0.5104, p<0.001) and fPSA% (r=-0.5059, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: